Transcriptional anti-angiogenesis therapy of human pancreatic cancer

Cytokine and Growth Factor Reviews

Volumn 17, Issue 3, 2006, Pages 147-156

  Xie, Keping ^a   Wei, Daoyan ^a   Huang, Suyun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Metastasis; Microenvironment; Sp1; Therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GENISTEIN; HYBRID PROTEIN; INTERLEUKIN 8 ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RIBOZYME; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR DIPHTHERIA TOXIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; VASCULOTROPIN ANTIBODY; VATALANIB;

AMINO ACID SEQUENCE; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CYTOKINE PRODUCTION; DRUG POTENTIATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; MICROENVIRONMENT; MUTATION; NONHUMAN; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANGIOGENESIS INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 33744525493     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2006.01.002     Document Type: Short Survey

References (100)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. CA Cancer J Clin 55 (2005) 10-30
2. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
3. Kuvshinoff B.W., and Bryer M.P. Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 7 (2000) 428-436
4. MacKenzie M.J. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5 (2004) 541-549
5. Sohn T.A., and Yeo C.J. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 9 (2000) 95-101
6. Sakorafas G.H., and Tsiotos G.G. Molecular biology of pancreatic cancer: potential clinical implications. Biodrugs 15 (2001) 439-452
7. Hruban R.H., Goggins M., Parsons J., and Kern S.E. Progression model for pancreatic cancer. Clin Cancer Res 6 (2000) 2969-2972
8. Kern S.E. Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 84 (2000) 691-695
9. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., and Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53 (1988) 549-554
10. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57 (1997) 1731-1734
11. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2 (2003) 8
12. Xie K., Wei D., Shi Q., and Huang S. Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15 (2004) 297-324
13. Xie K., and Huang S. Regulation of cancer metastasis by stress pathways. Clin Exp Metastasis 20 (2003) 31-43
14. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12 December (4) (2001) 375-391
15. Overholser J.P., Prewett M.C., Hooper A.T., Waksal H.W., and Hicklin D.J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89 (2000) 74-82
16. Bruns C.J., Solorzano C.C., Harbison M.T., Ozawa S., Tsan R., Fan D., et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60 (2000) 2926-2935
17. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 82 (1990) 4-6
18. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
19. Fang J., Yan L., Shing Y., and Moses M.A. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res 61 (2001) 5731-5735
20. Giordano F.J., and Johnson R.S. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 11 (2001) 35-40
21. Udagawa T., Fernandez A., Achilles E.G., Folkman J., and D'Amato R.J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 16 (2002) 1361-1370
22. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
23. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 10 (1993) 302-313
24. Seo Y., Baba H., Fukuda T., Takashima M., and Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (2000) 2239-2245
25. Linder S., Blasjo M., von Rosen A., Parrado C., Falkmer U.G., and Falkmer S. Pattern of distribution and prognostic value of angiogenesis in pancreatic duct carcinoma: a semiquantitative immunohistochemical study of 45 patients. Pancreas 22 (2001) 240-247
26. Fujioka S., Yoshida K., Yanagisawa S., Kawakami M., Aoki T., and Yamazaki Y. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 92 (2001) 1788-1797
27. Mirecka J., Libura J., Libura M., Koprowski M., Nowak D., Kedra B., et al. Morphological parameters of the angiogenic response in pancreatic ductal adenocarcinoma-correlation with histological grading and clinical data. Folia Histochem Cytobiol 39 (2001) 335-340
28. Stipa F., Lucandri G., Limiti M.R., Bartolucci P., Cavallini M., Di Carlo V., et al. Angiogenesis as a prognostic indicator in pancreatic ductal adenocarcinoma. Anticancer Res 22 (2002) 445-449
29. Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J.W., Richter A., et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25 (2002) 122-129
30. Khan A.W., Dhillon A.P., Hutchins R., Abraham A., Shah S.R., Snooks S., et al. Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur J Surg Oncol 28 (2002) 637-644
31. Kuwahara K., Sasaki T., Kuwada Y., Murakami M., Yamasaki S., and Chayama K. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26 (2003) 344-349
32. Shibaji T., Nagao M., Ikeda N., Kanehiro H., Hisanaga M., Ko S., et al. Prognostic significance of HIF-1 alpha overexpression in human pancreatic cancer. Anticancer Res 23 (2003) 4721-4727
33. Karademir S., Sokmen S., Terzi C., Sagol O., Ozer E., Astarcioglu H., et al. Tumor angiogenesis as a prognostic predictor in pancreatic cancer. J Hepatobiliary Pancreat Surg 7 (2000) 489-495
34. Ikeda N., Adachi M., Taki T., Huang C., Hashida H., Takabayashi A., et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79 (1999) 1553-1563
35. Ellis L.M., Takahashi Y., Fenoglio C.J., Cleary K.R., Bucana C.D., and Evans D.B. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 34 (1998) 337-340
36. Fujimoto K., Hosotani R., Wada M., Lee J.U., Koshiba T., Miyamoto Y., et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34 (1998) 1439-1447
37. Niedergethmann M., Hildenbrand R., Wolf G., Verbeke C.S., Richter A., and Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 28 (2000) 31-39
38. Knoll M.R., Rudnitzki D., Sturm J., Manegold B.C., Post S., and Jaeger T.M. Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology 48 (2001) 1162-1165
39. Tang R.F., Itakura J., Aikawa T., Matsuda K., Fujii H., Korc M., et al. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 22 (2001) 285-292
40. Balaz P., Friess H., and Buchler M.W. Growth factors in pancreatic health and disease. Pancreatology 1 (2001) 343-355
41. Banerjee S.K., Zoubine M.N., Mullick M., Weston A.P., Cherian R., and Campbell D.R. Tumor angiogenesis in chronic pancreatitis and pancreatic adenocarcinoma: impact of K-ras mutations. Pancreas 20 (2000) 248-255
42. Kitada T., Seki S., Sakaguchi H., Sawada T., Hirakawa K., and Wakasa K. Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma. Histopathology 43 (2003) 550-555
43. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S., et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 97 (2000) 9624-9629
44. Kasper H.U., Ebert M., Malfertheiner P., Roessner A., Kirkpatrick C.J., and Wolf H.K. Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch 438 (2001) 116-120
45. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., and Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5 (1999) 3711-3721
46. Xiong H.Q., Abbruzzese J.L., Lin E., Wang L., Zheng L., and Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 108 (2004) 181-188
47. Hotz H.G., Reber H.A., Hotz B., Sanghavi P.C., Yu T., Foitzik T., et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 5 (2001) 131-138
48. Egawa S., Tsutsumi M., Konishi Y., Kobari M., Matsuno S., Nagasaki K., et al. The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology 108 (1995) 1526-1533
49. Prox D., Becker C., Pirie-Shepherd S.R., Celik I., Folkman J., and Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27 (2003) 405-411
50. Chu J., Lloyd F.L., Trifan O.C., Knapp B., and Rizzo M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2 (2003) 1-7
51. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., and Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 64 (2004) 2030-2038
52. Buchler P., Reber H.A., Buchler M.W., Friess H., Lavey R.S., and Hines O.J. Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100 (2004) 201-210
53. Stoeltzing O., Liu W., Reinmuth N., Fan F., Parikh A.A., Bucana C.D., et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163 (2003) 1001-1011
54. Kisker O., Onizuka S., Banyard J., Komiyama T., Becker C.M., Achilles E.G., et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 61 (2001) 7298-7304
55. Onizuka S., Kawakami S., Taniguchi K., Fujioka H., and Miyashita K. Pancreatic carcinogenesis: apoptosis and angiogenesis. Pancreas 28 (2004) 317-319
56. Tomioka D., Maehara N., Kuba K., Mizumoto K., Tanaka M., Matsumoto K., et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res 61 (2001) 7518-7524
57. Salimath B., Marme D., and Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene 19 (2000) 3470-3476
58. Igarashi H., Esumi M., Ishida H., and Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95 July (1) (2002) 47-53
59. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
60. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 October (10) (2003) 721-732
61. Brahimi-Horn M.C., and Pouyssegur J. The hypoxia-inducible factor and tumor progression along the angiogenic pathway. Int Rev Cytol 242 (2005) 157-213
62. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
63. Shi Q., Le X., Wang B., Abbruzzese J.L., Xiong Q., He Y., et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene 20 (2001) 3751-3756
64. Shi Q., Le X., Wang B., Xiong Q., Abbruzzese J.L., and Xie K. Regulation of interleukin-8 expression by cellular pH in human pancreatic adenocarcinoma cells. J Interferon Cytokine Res 20 (2000) 1023-1028
65. Xie K., and Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 34 (2003) 969-986
66. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., and Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14 (1995) 263-277
67. Saimura M., Nagai E., Mizumoto K., Maehara N., Minamishima Y.A., Katano M., et al. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 8 (2002) 3243-3249
68. Le X., Shi Q., Wang B., Xiong Q., Qian C., Peng Z., et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20 (2000) 935-946
69. Sunamura M., Duda D.G., Ghattas M.H., Lozonschi L., Motoi F., Yamauchi J., et al. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis 6 (2003) 15-24
70. Aoki T., Nagakawa Y., Tsuchida A., Kasuya K., Kitamura K., Inoue K., et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol Rep 9 (2002) 761-765
71. Parikh A.A., Liu W.B., Fan F., Stoeltzing O., Reinmuth N., Bruns C.J., et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 98 (2003) 720-729
72. Reinmuth N., Fan F., Liu W., Parikh A.A., Stoeltzing O., Jung Y.D., et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82 (2002) 1377-1389
73. Teraoka H., Sawada T., Nishihara T., Yashiro M., Ohira M., Ishikawa T., et al. Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 85 (2001) 612-627
74. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2 (2000) 737-744
75. Ebert M.P., Fei G., Schandl L., Mawrin C., Dietzmann K., Herrera P., et al. Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 86 (2002) 257-262
76. Wen S., Stolarov J., Myers M.P., Su J.D., Wigler M.H., Tonks N.K., et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98 (2001) 4622-4627
77. Takeuchi Y., Nakao A., Harada A., Nonami T., Fukatsu T., and Takagi H. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 88 (1993) 1928-1933
78. Yang E.Y., and Moses H.L. Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111 (1990) 731-741
79. Lambert V., Munaut C., Noel A., Frankenne F., Bajou K., Gerard R., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15 (2001) 1021-1027
80. Andreasen P.A., Egelund R., and Petersen H.H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57 (2000) 25-40
81. Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I., and Rifkin D.B. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 51 (1997) 1376-1382
82. Kojima S., Nara K., and Rifkin D.B. Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 121 (1993) 439-448
83. Liu D., Aguirre Ghiso J., Estrada Y., and Ossowski L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (2002) 445-457
84. Bancroft C.C., Chen Z., Yeh J., Sunwoo J.B., Yeh N.T., Jackson S., et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99 (2002) 538-548
85. Hirata A., Ogawa S., Kometani T., Kuwano T., Naito S., Kuwano M., et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62 (2002) 2554-2560
86. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H., et al. Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61 (2001) 4143-4154
87. Suske G. The Sp-family of transcription factors. Gene 238 (1999) 291-300
88. Bouwman P., and Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol Cell Endocrinol 195 (2002) 27-38
89. Black A.R., Black J.D., and Azizkhan-Clifford J. Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188 (2001) 143-160
90. Li L., He S., Sun J.M., and Davie J.R. Gene regulation by Sp1 and Sp3. Biochem Cell Biol 82 (2004) 460-471
91. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
92. Salnikow K., Kluz T., Costa M., Piquemal D., Demidenko Z.N., Xie K., et al. The regulation of hypoxic genes by calcium involves c-Jun/AP-1, which cooperates with hypoxia-inducible factor 1 in response to hypoxia. Mol Cell Biol 22 (2002) 1734-1741
93. Blaudschun R., Sunderkotter C., Brenneisen P., Hinrichs R., Peters T., Schneider L., et al. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br J Dermatol 146 (2002) 581-587
94. Pluda J.M., and Parkinson D.R. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 78 (1996) 680-687
95. Keleg S., Buchler P., Ludwig R., Buchler M.W., and Friess H. Invasion and metastasis in pancreatic cancer. Mol Cancer 2 1 (2003) 14
96. Duffy J.P., Eibl G., Reber H.A., and Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2 1 (2003) 12
97. Fisher W.E., and Berger D.H. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int J Gastrointest Cancer 33 1 (2003) 79-88
98. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400 (1999) 468-472
99. Wong A.K., and Chin L. An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev 19 (2000) 121-129
100. Gunther E.J., Belka G.K., Wertheim G.B., Wang J., Hartman J.L., Boxer R.B., et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 16 (2002) 283-292